tiprankstipranks
Trending News
More News >
Siemens Healthineers AG (DE:SHL)
XETRA:SHL
Advertisement

Siemens Healthineers AG (SHL) AI Stock Analysis

Compare
81 Followers

Top Page

DE:SHL

Siemens Healthineers AG

(XETRA:SHL)

Select Model
Select Model
Select Model
Outperform 77 (OpenAI - 4o)
Rating:77Outperform
Price Target:
€54.00
▲(11.27% Upside)
Siemens Healthineers AG's strong financial performance and positive earnings call are the most significant factors contributing to the score. While technical analysis shows mixed signals, the company's strategic focus and raised outlook provide a positive long-term view. Valuation is reasonable, supporting the overall investment case.
Positive Factors
Negative Factors

Siemens Healthineers AG (SHL) vs. iShares MSCI Germany ETF (EWG)

Siemens Healthineers AG Business Overview & Revenue Model

Company DescriptionSiemens Healthineers AG, through its subsidiaries, develops, manufactures, and sells a range of diagnostic and therapeutic products and services to healthcare providers worldwide. The company operates through four segments: Imaging, Diagnostics, Varian, and Advanced Therapies. The Imaging segment provides magnetic resonance imaging, computed tomography, X-ray systems, molecular imaging, and ultrasound systems. The Diagnostics segment offers in-vitro diagnostic products and services to healthcare providers in laboratory, molecular and point-of-care diagnostics; and workflow solutions for laboratories and informatics products. The Varian segment provides cancer care technologies, and solutions and services to oncology departments in hospitals and clinics; and technology-enabled optimized workflows, clinical services and consulting capabilities, and digital solutions and applications for managing treatment and therapy. The Advanced Therapies segment offers products that are designed to support image-guided minimally invasive treatments in various areas, such as cardiology, interventional radiology, and surgery; and angiography systems and mobile C-arms, including a robotic-assisted platform for endovascular coronary and peripheral vascular interventions. It also provides equipment performance management, clinical education and e-learning, asset management, and managed departmental services for laboratories and healthcare facilities, as well as consulting and digital health services. The company is headquartered in Erlangen, Germany. Siemens Healthineers AG operates as a subsidiary of Siemens Aktiengesellschaft.
How the Company Makes MoneySiemens Healthineers generates revenue through multiple streams, primarily from the sale of medical devices and equipment, which includes imaging systems, laboratory diagnostics, and point-of-care testing solutions. The company also earns significant income from service agreements, which encompass installation, maintenance, and upgrades of their medical devices. Additionally, SHL benefits from software and digital health services that improve operational efficiency and patient outcomes for healthcare providers. Key partnerships with hospitals, research institutions, and other healthcare organizations further contribute to their earnings, enhancing their market presence and enabling access to large-scale contracts. The growing demand for innovative healthcare solutions, particularly in emerging markets, also plays a vital role in driving revenue growth for Siemens Healthineers.

Siemens Healthineers AG Earnings Call Summary

Earnings Call Date:Jul 30, 2025
(Q3-2025)
|
Next Earnings Date:Nov 05, 2025
Earnings Call Sentiment Positive
The earnings call reflects a strong overall performance with significant revenue growth, margin expansion, and strategic advancements, despite challenges such as tariff headwinds and underperformance in China and Diagnostics.
Q3-2025 Updates
Positive Updates
Strong Revenue Growth
Siemens Healthineers reported a Q3 revenue growth of 7.6% with all regions showing growth, outpacing their full-year growth target. Imaging revenue grew by nearly 12% and Varian saw a 9% growth. Adjusted EPS grew by 23% to EUR 0.64 per share.
Impressive Margins and Financial Performance
Despite a EUR 100 million tariff headwind, Siemens Healthineers achieved margin expansion with Imaging margins at 21% and Varian margins at 18.8%. The company also reported a strong free cash flow, reducing leverage below 3x for the first time since the Varian acquisition.
Innovation and Strategic Partnerships
The Atellica franchise in Diagnostics is growing double digits and accounts for 60% of core lab revenues. Siemens Healthineers' Value Partnerships have grown significantly, reshaping revenue streams into recurring revenue. The company has entered into over 200 Value Partnerships.
Photon Counting CT Success
Photon Counting CT has been a significant growth driver within the CT segment, contributing to high-end CT market share gains globally.
Negative Updates
Tariff Headwinds
The quarter faced a EUR 100 million headwind from tariffs, expected to increase to EUR 200-250 million in Q4. For fiscal year 2026, the tariff impact is projected to be EUR 400-500 million.
Challenges in China
Revenue in China continued to be flat at around EUR 620 million with no sustained market recovery evidence. The 6% growth is attributed to lower comps from the previous year.
Diagnostics Underperformance
Diagnostics saw a slightly negative growth due to volume-based procurement impacts in China, expected to persist into the next fiscal year. Margins in Diagnostics were helped by a positive one-off from pension liabilities.
Company Guidance
In the Siemens Healthineers Q3 2025 earnings call, the company reported robust performance with a 7.6% growth in revenue across all regions, surpassing their annual growth target. Adjusted earnings per share (EPS) increased by 23% to EUR 0.64 per share, despite a EUR 100 million headwind from tariffs. The equipment book-to-bill ratio remained strong at 1.09. Imaging saw a 12% revenue growth, with a margin of 21%, while Varian and Advanced Therapies achieved 9% and 4.5% revenue growth respectively. Diagnostics margins improved to 9.2%, but revenue slightly declined. Free cash flow was strong, reducing the leverage factor below 3x. The company raised its fiscal year 2025 outlook, anticipating 5.5% to 6% revenue growth and adjusted EPS of EUR 2.30 to EUR 2.45, accounting for tariff impacts. The call also highlighted Siemens Healthineers' strategic focus on patient twinning, precision therapy, and digital, data, and AI capabilities, emphasizing their role in enhancing patient outcomes and healthcare system efficiencies.

Siemens Healthineers AG Financial Statement Overview

Summary
Siemens Healthineers AG shows strong financial performance with consistent revenue and profit growth, efficient operational management, and a stable financial position. The company has a solid balance sheet and robust cash flow generation, although the increase in debt levels requires attention.
Income Statement
85
Very Positive
Siemens Healthineers AG demonstrates strong revenue growth with a TTM increase of 3.3% and consistent profitability, evidenced by a solid gross profit margin of 38.76% and a net profit margin of 9.29%. The EBIT and EBITDA margins are healthy at 14.48% and 20.02%, respectively, indicating efficient operational management. The company shows a positive trajectory in revenue and profit growth, enhancing its competitive position in the medical devices industry.
Balance Sheet
78
Positive
The balance sheet reflects a stable financial position with a manageable debt-to-equity ratio of 0.89, indicating prudent leverage. The return on equity is robust at 11.69%, showcasing effective use of shareholder funds. The equity ratio stands at 39.64%, suggesting a solid capital structure. However, the increase in total debt over the years warrants monitoring to ensure continued financial stability.
Cash Flow
80
Positive
Cash flow analysis reveals a strong free cash flow growth rate of 11.10% TTM, supporting the company's ability to fund operations and investments. The operating cash flow to net income ratio of 1.56 and free cash flow to net income ratio of 0.77 indicate efficient cash generation relative to earnings. The company maintains a healthy cash flow position, crucial for sustaining growth and operational flexibility.
BreakdownTTMDec 2024Dec 2023Dec 2022Dec 2021Dec 2020
Income Statement
Total Revenue23.38B22.36B21.68B21.71B18.00B14.46B
Gross Profit9.06B8.47B7.71B8.14B6.95B5.58B
EBITDA4.68B4.22B3.78B4.26B3.52B2.84B
Net Income2.17B1.94B1.51B2.04B1.73B1.41B
Balance Sheet
Total Assets44.60B46.05B46.68B49.06B41.93B25.09B
Cash, Cash Equivalents and Short-Term Investments2.37B2.68B1.64B1.44B1.32B656.00M
Total Debt15.70B16.21B16.65B16.65B14.31B5.50B
Total Liabilities26.88B27.81B28.55B29.20B25.87B12.58B
Stockholders Equity17.68B18.20B18.08B19.84B16.04B12.50B
Cash Flow
Free Cash Flow2.62B1.77B971.00M1.40B2.11B1.25B
Operating Cash Flow3.39B2.47B1.81B2.26B2.78B1.80B
Investing Cash Flow-965.00M-666.00M-1.07B-868.00M-14.14B-1.91B
Financing Cash Flow-1.99B-1.30B-380.00M-1.40B11.99B-126.00M

Siemens Healthineers AG Technical Analysis

Technical Analysis Sentiment
Positive
Last Price48.53
Price Trends
50DMA
47.04
Positive
100DMA
46.90
Positive
200DMA
48.82
Negative
Market Momentum
MACD
0.10
Negative
RSI
62.64
Neutral
STOCH
99.20
Negative
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For DE:SHL, the sentiment is Positive. The current price of 48.53 is above the 20-day moving average (MA) of 47.04, above the 50-day MA of 47.04, and below the 200-day MA of 48.82, indicating a neutral trend. The MACD of 0.10 indicates Negative momentum. The RSI at 62.64 is Neutral, neither overbought nor oversold. The STOCH value of 99.20 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for DE:SHL.

Siemens Healthineers AG Peers Comparison

Overall Rating
UnderperformOutperform
Sector (51)
Financial Indicators
Name
Overall Rating
Market Cap
P/E Ratio
ROE
Dividend Yield
Revenue Growth
EPS Growth
77
Outperform
$53.91B24.9511.75%1.96%5.85%16.20%
70
Outperform
€13.28B20.374.83%3.11%0.53%23.79%
70
Neutral
€14.18B122.303.88%0.40%3.80%33.31%
69
Neutral
€25.98B23.617.30%2.16%-0.59%
67
Neutral
€4.08B25.767.48%1.33%5.21%-39.36%
65
Neutral
€52.26B18.3510.08%1.84%1.67%9.02%
51
Neutral
$7.86B-0.30-43.30%2.27%22.53%-2.21%
* Healthcare Sector Average
Performance Comparison
Ticker
Company Name
Price
Change
% Change
DE:SHL
Siemens Healthineers AG
48.53
-1.96
-3.87%
DE:AFX
Carl Zeiss Meditec
45.08
-20.02
-30.75%
DE:FME
Fresenius Medical Care AG & Co. KGaA
46.25
10.77
30.36%
DE:FRE
Fresenius SE & Co. KGaA
46.31
13.33
40.43%
DE:MRK
Merck KGaA
119.25
-32.44
-21.39%
DE:SRT
Sartorius
181.40
-4.02
-2.17%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.Date of analysis: Oct 03, 2025